FGSCX
Price
$24.62
Change
+$0.03 (+0.12%)
Updated
Sep 20 closing price
RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
Ad is loading...

FGSCX vs RPTIX

Header iconFGSCX vs RPTIX Comparison
Open Charts FGSCX vs RPTIXBanner chart's image
Federated Hermes MDT Mid Cap Growth C
Price$24.62
Change+$0.03 (+0.12%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
FGSCX vs RPTIX Comparison Chart
Loading...
VS
FGSCX vs. RPTIX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FGSCX is a Buy and RPTIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. FGSCX (1.69B). RPTIX pays higher dividends than FGSCX: RPTIX (0.18) vs FGSCX (0.00). FGSCX was incepted earlier than RPTIX: FGSCX (29 years) vs RPTIX (9 years). FGSCX is a more actively managed with annual turnover of: 142.00 vs. RPTIX (21.70). FGSCX has a lower initial minimum investment than RPTIX: FGSCX (1500) vs RPTIX (500000). FGSCX annual gain was more profitable for investors over the last year : 35.05 vs. RPTIX (14.81). RPTIX return over 5 years is better than : 15.09 vs. FGSCX (-10.28).
FGSCXRPTIXFGSCX / RPTIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence29 years9 years-
Gain YTD17.7439.127194%
Front LoadN/AN/A-
Min. Initial Investment15005000000%
Min. Initial Investment IRAN/AN/A-
Net Assets1.69B31.4B5%
Annual Yield % from dividends0.000.18-
Returns for 1 year35.0514.81237%
Returns for 3 years-30.65-13.57226%
Returns for 5 years-10.2815.09-68%
Returns for 10 years-38.19N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp